На главную
Результаты поиска “Adjuvant hormonal therapy in prostate cancer”
Hormone Therapy For Prostate Cancer Treatment- Hormone Therapy Side Effects
 
00:42
Now we have a number of medications available as pills, injections, and implants that can give men the hormonal therapy is also sometimes given after radiotherapy (adjuvant therapy), where aim to reduce chance cancer coming back. Because of their possible side effects (including blood clots and breast enlargement), estrogens have been replaced by other types hormone therapy are you consider as a treatment for prostate cancer? Here is information about the that may experience this get better within 3 to 12 months after ends. And difficulty getting or keeping an erection. His presentation was certainly the most controversial and provocative of session. Zero the end of prostate cancer. How does hormone therapy treat prostate cancer? 4. Make sure you discuss these with your doctor or nurse before start treatment. Your doctor prostate cancer depends on the hormone testosterone in order to grow. Advantages and disadvantages of hormone therapymonitoring the effects therapymanaging side therapycomplementary alternative therapies 15 aug 2017 to minimize therapy medications, your doctor may recommend you take them only until prostate cancer responds treatment. The side effects of hormone therapy and the time it takes to get over some them depend on many factors. Hormone therapy for localised prostate cancer further detailed understanding hormone. Hormonal therapies for advanced prostate cancer information and hormone therapy harvard knowledge canada. You can also talk to our specialist nurses about side effects. Estrogens (female hormones) were once the main alternative to orchiectomy for men with advanced prostate cancer. What does hormone therapy involve? 6. Hormonal therapy can cause a range of side effects that include erection difficulties (ed), lowered sex drive, hot flushes, weight gain, breast swelling and fatigue once reserved solely as treatment for metastatic prostate cancer, hormone is now also used in variety other ways. What are the side effects of hormone therapy for prostate cancer? Loss interest in sex (lowered libido) erectile dysfunctionloss bone densityloss muscle mass and physical strengthinsulin resistance 11 mar 2016 other androgen suppressing drugs. Your doctor or clinical nurse specialist will be able to offer you advice. Typically, you can of the treatment. Hormone therapy what are the side effects? Prostate cancer effects of hormone in men how affects you. He stated that testosterone might not adding radiation therapy to hormone increases survival among men with locally advanced prostate cancer. It depends on the drug you are having and how long have been taking it. For some men, erection problems are permanent. Anti androgens can cause less sexual side effects as agonists but are not effective an orchiestomy or lhrh in treating the disease, leaving it a poor hormonal therapy is main treatment for advanced prostate cancer. We describe here the most common side effects of hormone therapy and how to manage or reduce them. Effective
Просмотров: 381 health tips
Urowebinar: Hormone therapy in prostate cancer  who, how and when
 
41:09
Presenter: Dr. Vijay Ramani Androgens promote the growth of both normal and cancerous prostate cells by binding to and activating the androgen receptor. Once activated, the androgen receptor stimulates the expression of specific genes that cause prostate cells to grow. Hormone therapy, also called androgen deprivation therapy, can block the production and use of androgens inhibiting the cell growth. Different types of androgen deprivation therapy are available in different modalities: neoadjuvant and adjuvant setting, or as a single agent therapy. How to choose the best treatment’s agent, modality and timing will be clarified in this comprehensive webinar.
Просмотров: 1200 European School of Urology
How Is Hormone Therapy Used To Treat Prostate Cancer?
 
38:45
http://www.balancedhealthtoday.com http://www.balancedhealthtoday.com/endosterol.html Hormone therapy may be used in several ways to treat prostate cancer, including: Adjuvant hormone therapy. Hormone therapy that is given after other primary treatments to lower the risk that prostate cancer will come back is called adjuvant hormone therapy. Men with early-stage prostate cancer that has an intermediate or high risk of recurrence may receive adjuvant hormone therapy after radiation therapy or prostatectomy (surgery to remove all or part of the prostate gland) (5). Factors that are used to determine the risk of prostate cancer recurrence include the tumor's grade (as measured by the Gleason score), the extent to which the tumor has spread into surrounding tissue, and whether or not tumor cells are found in nearby lymph nodes. Men who have adjuvant hormone therapy after prostatectomy live longer without having a recurrence than men who have prostatectomy alone, but they do not live longer overall (5). Men who have adjuvant hormone therapy after external beam radiation therapy for prostate cancer live longer, both overall and without having a recurrence, than men who are treated with radiation therapy alone (5, 6). Neoadjuvant hormone therapy. Hormone therapy given before other treatments is called neoadjuvant hormone therapy. Men with early-stage prostate cancer that has an intermediate or high risk of recurrence often receive hormone therapy before or during radiation therapy, in addition to receiving hormone therapy after radiation therapy. Men who receive hormone therapy in combination with radiation therapy live longer overall than men who receive radiation therapy alone (7). The use of neoadjuvant hormone therapy (alone or in combination with chemotherapy) before prostatectomy has not been shown to prolong survival and is not a standard treatment. Hormone therapy alone. Hormone therapy is sometimes used alone for palliation or prevention of local symptoms in men with localized prostate cancer who are not candidates for surgery or radiation therapy (8). Such men include those with a limited life expectancy, those with advanced local tumor stage, and/or those with other serious health conditions. Hormone therapy used alone is also the standard treatment for men who have a prostate cancer recurrence documented by CT, MRI, or bone scan after treatment with radiation therapy or prostatectomy. Hormone therapy is often recommended for men who have a "biochemical" recurrence—a rapid rise in prostate-specific antigen (PSA) level—especially if the PSA level doubles in fewer than 12 months. However, a rapid rise in PSA level does not necessarily mean that the prostate cancer itself has recurred. The use of hormone therapy in the case of a biochemical recurrence is somewhat controversial. Finally, hormone therapy used alone is also the standard treatment for men who are found to have metastatic disease (i.e., disease that has spread to other parts of the body) when their prostate cancer is first diagnosed (9). Whether hormone therapy prolongs the survival of men who have been newly diagnosed with advanced disease but do not yet have symptoms is not clear (10, 11). Moreover, because hormone therapy can have substantial side effects (see Question 6), some men prefer not to take hormone therapy before symptoms develop. http://www.balancedhealthtoday.com/store http://www.balancedhealthtoday.com/store/endosterol.html
Просмотров: 294 Martina Santiago
Hormone deprivation  for prostate cancer is dangerous. Avoid it!
 
21:50
Hormone deprivation for prostate cancer is dangerous. Avoid it There is a common misunderstanding on the role of hormones in cancer. Here are some simple rules. 1. Tumor inherits its hormone dependence from the organ where it was formed. Like breast tumor responds to breast hormones like estrogen. 2. Hormones are not carcinogens and do not initiate cancer. They merely accelerate tumor growth, which is known as tumor promotion 2a.Carcinogens initiate a tumor by transforming a normal cell into a malignant. Hormones do not transform cells. They merely promote the growth of transformed cells. 2b. Hormone depletion does not cure cancer. It retards tumor growth and may induce tumor dormancy. 3. As cancer progresses, tumor dependency on hormones declines 3a. This tumor property is known as de-differentiation, which makes tumor independent from hormones. Anti-hormones do not cure cancer, but they may induce tumor dormancy. Unfortunately oncology ignores these rules. Many healthy men carry dormant tumors in their prostates Current treatments, like androgen deprivation, radiation and surgery do not cure cancer. They cannot prevent cancer recurrence and their harm outweighs their benefit. When tumor is confined to the prostate brachytherapy is the treatment of choice. decades. Every second male older than 60 years carries in his prostate a dormant tumor. How did he do it and what is his secret? This capability exists in every male even if he got clinical cancer. It is our duty to harness it during therapy. .
Просмотров: 4592 Gershom Zajicek M.D,
Hormonal therapy in breast cancer
 
20:17
This video describes therapy with anti-estrogens medications in breast cancer.
Просмотров: 24572 charlottecancer
First effective adjuvant chemotherapy for high-risk, localised prostate cancer
 
03:45
Visit http://www.ecancer.org for more Prof Sandler (Cedars Sinai Medical Center, Los Angeles, USA) presents, at a press conference at ASCO 2015, the results of a federally funded phase III study that found that adding docetaxel chemotherapy to standard hormone and radiation therapy reduces the risk of death for men with high-risk, localised prostate cancer.
Просмотров: 79 ecancer
Hormone Treatment
 
03:19
Hormone treatments can help men with advanced prostate cancer.
Просмотров: 3366 ZERO - The End of Prostate Cancer
Adjuvant or Salvage RT Post Radical Prostatectomy
 
25:08
Seth R. Blacksburg, MD, MBA, discusses the clinical significance of biochemical failure post-radical prostatectomy (RP). He then reviews the literature comparing the advantages and disadvantages of adjuvant and salvage radiation therapy (RT) for biochemical recurrence. Furthermore, he summarizes consensus guidelines, meta level considerations and debates regarding adjuvant and salvage RT, and prospective trials.
Просмотров: 117 Grand Rounds in Urology
Docetaxil in hormone therapy improves survival in metastatic, hormone-sensitive prostate cancer
 
07:53
Visit http://ecancer.org/ for more. At a press conference at ASCO 2014, Prof Sweeney (Dana-Farber Cancer Institute, Boston, USA) presents the findings of an ECOG-led phase III randomised trial which indicate that adding the chemotherapy drug docetaxel to standard hormone therapy extends survival for men with newly diagnosed hormone-sensitive prostate cancer by roughly 10 months.
Просмотров: 345 ecancer
Chemohormonal therapy for hormone-sensitive newly metastatic prostate cancer
 
05:18
Ten years after pivotal results of docetaxel in castration-resistant prostate cancer, J.Bellmunt discusses results of chemohormonal therapy in patients with hormone-sensitive, newly diagnosed metastatic prostate cancer, noting how rare such magnitude of effect is seen in oncology. http://www.esmo.org Video produced by the European Society for Medical Oncology (ESMO)
Просмотров: 908 European Society for Medical Oncology
Dr. Patel on Early Treatment With Docetaxel for Metastatic Prostate Cancer
 
02:09
Jyoti D. Patel, MD, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the early treatment of patients with metastatic prostate cancer. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 300 Targeted Oncology
Using endocrine therapy in the treatment of patients with prostate cancer
 
05:03
Seth O. Fagbemi, MD, Marshfield Clinic Oncology/Hematology, discusses the use of endocrine therapy in the treatment of prostate cancer. This discussion comes in the context of describing robotic-assisted radical prostatectomy. Endocrine therapy is defined by the National Cancer Institute as "Treatment that adds, blocks, or removes hormones. For certain conditions (such as diabetes or menopause), hormones are given to adjust low hormone levels. To slow or stop the growth of certain cancers (such as prostate and breast cancer), synthetic hormones or other drugs may be given to block the bodys natural hormones. Sometimes surgery is needed to remove the gland that makes a certain hormone. Also called hormonal therapy, hormone therapy, and hormone treatment."
Просмотров: 209 Marshfield Clinic
Post Prostatectomy Radiation
 
31:16
Dr. Patrick W. McLaughlin presented "Post Prostatectomy Radiation" at the 22nd Annual Scottsdale Prostate Cancer Symposium on Saturday, March 18, 2017.
Просмотров: 1013 Grand Rounds in Urology
PSA Levels After Prostate Cancer Treatment
 
04:03
Dr. Tutrone explains how different types of treatment require different PSA levels to be considered cured, as well as how long PSA levels have to be monitored for recurrence of prostate cancer. LAST WEEK'S VIDEO - Prostatectomy Recovery Explained http://youtu.be/hDc5sBUxejY SUBSCRIBE FOR MORE EXPERT INFORMATION AND BREAKING PROSTATE CANCER NEWS http://www.youtube.com/subscription_center?add_user=ProstateCancerLive VISIT PROSTATECANCERLIVE.com FOR TONS OF INFORMATIVE VIDEOS http://www.prostatecancerlive.com/# SUGGEST THE NEXT TOPIC FOR OUR PROSTATE CANCER EXPERTS! http://www.prostatecancerlive.com/# CONNECT WITH US! Google+: http://bit.ly/17F4WQr Facebook: https://www.facebook.com/pages/Prostate-Cancer-Live/107234326132305 Twitter: https://twitter.com/ProstateLive ______ Disclaimer: This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician.
Просмотров: 17733 Prostate Cancer Live
Hormonal Therapy and Prostate Cancer
 
02:23
Dr. Matthew Cooney discusses how hormone therapy is used for prostate cancer and how to minimize treatment side effects. http://prostatecancerletter.com/
Просмотров: 151 Matthew Cooney
Radiation Therapy Side Effects for Prostate Cancer Patients
 
06:32
Michael Steinberg, M.D. - UCLA educates patients on the side effects of radiation therapy.
Просмотров: 67778 Prostate Cancer Research Institute
Hormone Therapy for Breast Cancer and the Side Effects of Tamoxifen
 
03:42
Dr. VK Gadi discusses breast cancer treatment with hormone therapy and the side effects associated with the use of Tamoxifen. Learn more about breast cancer: http://ow.ly/yC1S3092JIW Subscribe to our channel: http://ow.ly/cw9B308MFsc
Просмотров: 3426 Seattle Cancer Care Alliance
ESTRO 2010: Radiation treatment of prostate cancer
 
13:03
Dr Jereczek-Fossa speaks about the use of radiotherapy to treat prostate cancer, the importance of image guidance and the role it plays in adjuvant post operative treatment. Dr Jereczek-Fossa also explains the choice patients face whether to have robotic surgery or image guided radiotherapy, considers the option of adjuvant surgery after radiotherapy and discusses the benefits of anti-androgen hormone therapy that have been revealed in recent clinical trials. Dr Barbara Jereczek-Fossa of the European Institute of Oncology in Milan, Italy, speaking to ecancer.tv at the European Society for Therapeutic Radiology and Oncology meeting (ESTRO 29), in Barcelona.
Просмотров: 764 ecancer
Management after radical prostatectomy: early adjuvant radiotherapy or wait-and-see?
 
05:47
Dr Mohammad Parvez Shaikh, (Loyola University Medical Centre, Maywood, USA) talks to ecancertv at ASCO GU 2015 about cancer management after radical prostatectomy. He discusses his meta-analysis on the difference between early adjuvant radiotherapy versus watchful waiting management strategies.
Просмотров: 1594 ecancer
Prostate cancer hormone treatment heart risks | Dana-Farber Cancer Institute
 
02:31
Recent studies had suggested that hormone-blocking therapy for prostate cancer could raise the risk of fatal heart attacks. Paul Nguyen, MD and Toni Choueiri, MD, discuss their findings that androgen deprivation therapy (ADT) makes no difference to the rate of cardiovascular deaths in men receiving ADT compared with those who didn't. There is still a question of whether ADT elevates the risk of fatal heart attacks in patients with a history of heart disease. Read more: http://www.dana-farber.org/Newsroom/News-Releases/New-study-reassures-on-heart-risks-of-prostate-cancer-treatment.aspx
Просмотров: 485 Dana-Farber Cancer Institute
Optimizing Androgen Deprivation Therapy in High-Risk Prostate Cancer
 
07:25
In this segment, panelists discuss the optimization of treatments administered for patients with high-risk prostate cancer following progression on definitive therapies, such as radical prostatectomy. For more from this discussion, visit http://www.onclive.com/peer-exchange/prostate-guidelines
Просмотров: 610 OncLiveTV
Dr. Sweeney on Chemotherapy in Prostate Cancer
 
01:09
Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses when to give docetaxel as a treatment option for patients with prostate cancer.
Просмотров: 108 OncLiveTV
Keeping Metastatic Prostate Cancer at Bay
 
04:17
Ron was first diagnosed with aggressive prostate cancer nearly two decades ago at the age of 55. Today, Ron is taking apalutamide (Erleada) to prevent the cancer from metastasizing. Learn more in the AACR Cancer Progress Report 2018, www.CancerProgressReport.org.
Просмотров: 2603 American Association for Cancer Research
How to Treat Prostate Cancer|prostate cancer natural treatment options
 
03:20
How to Treat Prostate Cancer|prostate cancer natural treatment options If you or a loved one has recently been diagnosed with prostate cancer, you’re likely overwhelmed by all the different treatment options available. In order to choose the best treatment option, work with multiple doctors to fully understand the potential benefits and drawbacks of each option with attention to your specific diagnosis. While surgery and radiation therapy are the most common treatments used to treat prostate cancer, you may find that a blend of multiple treatment options work best for you.[1] In some cases, depending on your age and overall health and the type and stage of your cancer, you and your doctor may decide that the best course of action is simply to monitor the cancer without active treatment. 1 Familiarize yourself with hormone therapy options. Hormone therapy prevents cancer cells from getting the hormones, namely testosterone, that they need to grow. Cutting off or reducing the supply of these hormones can help kill or reduce the growth of cancer. There are several different types of hormone therapy.[7] Consider an orchiectomy. The surgical removal of your testicles is an immediate way to reduce the amount of testosterone in your body. With the guidance of a specialist, choose between medications that stop your body from producing testosterone (luteinizing hormone-releasing hormone agonists) and those that block testosterone from reaching the cancer cells (anti-androgens). Consider hormone therapy as an especially viable option to fight advanced prostate cancer. In some cases, your doctor may recommend using hormone therapy before radiation therapy to make radiation more successful. This type of treatment strategy is called neoadjuvant therapy. 2 Consider cryotherapy. Otherwise known as cryosurgery, this treatment option involves the insertion of probes into the prostate. Argon gas or liquid nitrogen are then used to freeze the prostate and kill any tumor cells therein.[8] Talk to your doctor about the potential risks of cryotherapy. The likelihood of erectile dysfunction and urinary complications are relatively high, and this treatment method has less certain long-term outcomes. Consider cryotherapy as a secondary option, particularly following unsuccessful radiation therapy. Those with early-stage cancer and well-confined tumors are more likely to benefit from this method of treatment 3 Use a focused ultrasound to kill cancer cells. This treatment option focuses high-intensity sound waves on cancer cells to burn them to death. It requires a probe to be inserted into the rectum, from which a powerful ultrasound targets the prostate cancer.[9] Though slow to take on elsewhere, this treatment option has demonstrated success in treating European patients. Consider this a secondary treatment option, as potential side effects include erectile dysfunction and urinary complications, and this method is much less practiced then radiation therapy and other options. SUBSCRIBE TO MORE VIDEOS
Просмотров: 20 health gym
When Should I Stop Anti-Hormone Therapy?
 
03:18
Find out more about Breast Cancer Index (BCI): http://www.breastcanceranswers.com/breastcancerindex/ When should you stop taking Anti-Hormone Therapy treatment for you breast cancer? Find out from Dr. Jay Harness in the video above. SUBSCRIBE FOR MORE EXPERT INFORMATION AND BREAKING BREAST CANCER NEWS http://www.youtube.com/user/drjayharness VISIT BREASTCANCERANSWERS.com FOR THE LATEST IN BREAKING BREAST CANCER NEWS http://www.breastcanceranswers.com/news SUBMIT A QUESTION http://www.breastcanceranswers.com/ DOWNLOAD DR. HARNESS' 15 QUESTIONS TO ASK YOUR DOCTOR http://www.breastcanceranswers.com/ CONNECT WITH US! Google+: http://bit.ly/16nhEnr Facebook: https://www.facebook.com/BreastCancerAnswers Twitter: https://twitter.com/BreastCancerDr
Просмотров: 360 Breast Cancer Answers®
Prostate Cancer: Radiation After Radical Prostatectomy- Is it Worthwhile?
 
05:30
The results of a large randomized study have been re-analyzed with new findings. Find out the results and their significance.
Просмотров: 7319 Gerald Chodak MD
Breast Cancer - Hormonal Therapy
 
02:43
Просмотров: 95 TeachGlobal
Key Developments in Non-Metastatic & Metastatic Hormone-Sensitive Prostate Cancer
 
22:36
The group discuss a series of phase II trials, predictive biomarkers and signpost emerging therapies from the congress. The discussion begins with reference to a Scandinavian adjuvant study (SPCG-13). Which was a randomised phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer. The group comments that the trial was negative and did not improve BDFS. The panel also highlight the continued data from LATITUDE where a detailed analyses was discussed by our panel with the key conclusions that adding AA + P to ADT delays the need for subsequent PC therapy vs ADT for pts with NDx-HR mCNPC. Time to subsequent therapy, life-prolonging therapy, and chemo strongly favoured AA + P, even though most pts receiving PBOs remaining on treatment had crossed over to AA + P or other life-prolonging subsequent therapy. The theme of ASCO was precision medicine and the group close the discussions with the PROPHECY trial. A multicentre prospective trial of circulating tumour cells (CTC) AR-V7 detection in men with mCRPC receiving abiraterone or enzalutamide. Finally the group remark on Study 8 (olaparib & abiraterone trial) and the KEYNOTE-199 (pembrolizumab for docetaxel-refractory mCRPC) and highlight that we will need to wait for further data to emerge on both PARPi and Immunotherapies.
Просмотров: 31 ecancer
Dr. Sandler on Docetaxel With Hormonal and Radiation Therapy in Prostate Cancer
 
01:32
Howard Sandler, MD, MS, FASTRO, chair, Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, discusses a results from a phase III study on docetaxel with hormonal and radiation therapy in prostate cancer.
Просмотров: 263 OncLiveTV
Hormonal Therapy for Breast Cancer by Lange Productions
 
00:47
Hormonal Therapy for breast cancer by Lange Productions
Просмотров: 693 LangeProductions
How Do Hormones Treat Cancer?
 
00:46
Hormone therapies for breast cancer treatment hormonal therapy treating hormone health encyclopedia and webmd. Hormone therapy cancer research uk. Analogs of gonadotropin releasing hormone (gnrh) can be used to induce a chemical castration, that is. At cancer treatment centers of america (ctca), we may hormonal therapies do have side this is also associated with how can hormones affect the growth breast cancer? Hormones like therapy be called anti hormone. Hormone therapy on its own won't cure your prostate hormonal in oncology is hormone for cancer and one of the major modalities it was formerly used breast treatment, but has since been replaced by more selective aromatase inhibitors. Having the right information will help you make decision for if testosterone is taken away, cancer usually shrink, even it has spread to other parts of your body. Hormonal therapy hematology & medical oncology cancer hormone national breast foundationoncolink. Hormone therapy can learn how hormone therapies slow or stop the growth of for breast cancer treatment is different than menopausal 14 feb 2017 hormonal medicines treat receptor positive cancers hrt contains estrogen and contain progesterone other in cases, hormones kill cells, make cells grow more slowly, them from growing. Hormone therapy as a cancer treatment may 10 apr 2015 tamoxifen and breast prevention; Can other drugs prevent common hormone for include but even in cases where removing or killing the isn't possible, can help slow down growth. Think of it as the 4 apr 2016 meanwhile, research is ongoing to study potential efficacy hormonal manipulation in treating other cancer types. Hormone therapy what are the side effects? Prostate cancer breast treatment hormone is hormonal for cancer? Hormonal early stage receptor. Hormone therapy cancer treatment centers of america. Hormone therapy for cancer national institute. Hormonal therapies treating breast cancer macmillan hormone therapy hormonal (oncology) wikipedia. Hormone therapy for breast cancer american society. Hormone treatment fights prostate cancer webmd. Hormone therapy cancer research ukcancer uk. Though it isn't a cure, hormone are you consider therapy as treatment for prostate cancer? Exercise is probably the best thing man can do to prevent many of these side effects oestrogen play part in stimulating some breast cancers grow, there number different therapies that work 20 jul 2016 hormonal medicines whole body receptor positive cancerslowering amount estrogen or blocking its also reduce risk an early stage, 16 feb adjuvant given after surgery, chemotherapy, and therapy, likely effects, how long will last, your doctors may tell options. Cancers that can be hormone sensitive include 18 aug 2016 therapy also used to treat cancer has come back after about 2 out of 3 breast cancers are receptor positive 29 apr 2015 is prostate and use the side effects you have will depend on type prevent cells from getting hormones they need grow. Hormone therapy changes hormone levels in the body and can stop or slow down doctors use it to treat some cancers such as breast prostate cancer is a treatment that uses medicines block lower does not work for all.
Просмотров: 50 Pan Pan 3
Biochemical Recurrence
 
04:25
Biochemical recurrence happens when a man's PSA levels rise after being treated by prostate cancer.
Просмотров: 2803 ZERO - The End of Prostate Cancer
Intermittent Hormone Therapy for Rising PSA:  Is it a Good Option?
 
02:36
When the PSA begins to rise after surgery or radiation, many men are told to begin hormone therapy. Some studies suggested that the hormones could be used intermittently rather than continuously. Now a well done study provides important new information for men faced with this problem as discussed in the video.
Просмотров: 957 Gerald Chodak MD
Surgery Versus Radiation in Prostate Cancer
 
02:00
Richard G. Stock, a radiation oncologist with Mount Sinai Hospital, says prostate cancer surgery isn't your typical type of cancer resection. Because the prostate's location and proximity to blood vessels and nerves, it's very difficult for surgeons to remove the prostate tumor and get a clean margin around the tissue, he says. "There are some limitations from a cancer standpoint," he says. "And many patients who have surgery may have microscopic disease left behind and may require adjuvant treatment such as hormone therapy or external beam radiation therapy afterward." Surgery has its side effects, he says, including possible incontinence and sexual dysfunction. Radiation is less invasive, however, it has its own side effects.
Просмотров: 1665 curetoday
Dr. Mary-Ellen Taplin on Neoadjuvant ADT Plus Hormonal Therapy for Prostate Cancer
 
01:49
Mary-Ellen Taplin, MD, associate professor of Medicine at Harvard Medical School and the Dana-Farber Cancer Institute, explains the rationale behind the recent study examining the neoadjuvant administration of abiraterone acetate (Zytiga) in combination with the LHRH analog leuprolide acetate, for patients with localized high-risk prostate cancer. To read more, visit http://www.onclive.com/onclive-tv/Dr-Taplin-on-Neoadjuvant-ADT-Plus-Hormonal-Therapy
Просмотров: 295 OncLiveTV
Docetaxel + hormone & radiation therapy, for high-risk prostate cancer.
 
04:30
Chicago ASCO Annual Meeting 2015: Press Briefing Progress Against Rare and Common Cancers: Saturday, May 30 - Howard M. Sandler, Chen Hu, Seth A. Rosenthal, et al. A phase III study of adjuvant docetaxel chemotherapy, added to standard hormone and radiation therapy, for men with localized, high-risk prostate cancer. More info: http://oncoletter.ch
Просмотров: 373 oncoletter
Multimodal Approach to Advanced Prostate Cancer
 
50:33
Martin E. Gleave, MD, FRCSC, FACS, discusses his views on improving advanced prostate cancer treatment approaches. Specifically, he emphasizes methods that integrate various treatment options beyond surgical castration and androgen deprivation therapy (ADT).
Просмотров: 241 Grand Rounds in Urology
Hormone Therapy for breast cancer
 
03:26
New Zealand women talk about their experiences of hormone therapy for breast cancer. Breast Cancer Aotearoa Coalition (New Zealand) http://www.breastcancer.org.nz/
Просмотров: 1555 nzbreastcancer
Prostate Cancer: PSA After Surgery
 
04:15
How necessary is the PSA blood test after treatment of prostate cancer? Why do some PSA levels fluctuate after surgery? Listen to Dr. Hafron explain in this clip from our April Prostate Cancer Survivorship Series.
Просмотров: 5262 MIU Men's Health Foundation
SABCS: Debu Tripathy Discusses Hormonal Therapy Advances in Breast Cancer
 
02:34
Debu Tripathy reports on recent studies involving hormone therapy in estrogen receptor-positive breast cancer. Two trials, called SOFT and TEXT were combined and long-term follow up results were announced at the San Antonio Breast Cancer Symposium. In the combined results, certain groups of patients, but not all, did seem to receive a benefit with tamoxifen in addition to shutting down the ovaries. "This is an important conversation for patients to have when they are completing their therapy if their tumor is hormone-sensitive, and they're going to be getting hormone therapy and they're pre-menopausal (they're still having their periods)," he says. "For some patients, this may help."
Просмотров: 382 curetoday
Hormone Therapy - Part 4 - Breast Cancer Prevention
 
09:25
Part 4 of 9 -- Dr. Lisa Lilienfield of the Kaplan Center for Integrated Medicine talks about hormonal functions and balancing as an essential part of health. Often patients suffering from chronic pain, illness, or fatigue have been living with hormonal imbalances that have never been properly diagnosed. She discusses hormone therapy, the current research on hormone replacement, the side effects of hormone reduction as people age, and some of the laboratory testing used to explore whether a hormonal imbalance is causing or contributing to a condition. Dr. Lilienfield also discusses the use of synthetic as well as bio identical hormones in hormone replacement therapy.
Просмотров: 746 KaplanCenter
Prostate cancer radiation treatment
 
09:42
External beam radiotherapy. First 3-4 minutes are only quick xrays to verify organ locations and alignment. Once they move the bars out of the way (thumbs up from the tech) the machine moves to the programmed starting point and the treatment (extended beep) begins. I have 9 treatment angles. Enjoy!
Просмотров: 13077 n8ofg
Adjuvant docetaxel fails after radical prostatectomy for high risk prostate cancer
 
07:13
Dr Ahlgen speaks with ecancertv at ASCO 2016 about the results of SPCG12, a randomised phase III trial assessing patient survival following radical prostatectomy with docetaxel. Docetaxel has previously proved to efficacious in prolonging survival in advanced castrate resistant prostate cancer (PCa), but Dr Ahlgren reports that, in Kaplan-Meier analysis, there was no significant difference between patients receiving docetaxel after prostatectomy or those receiving surveillance and care. He highlights that docetaxel as a monotherapy seems to generate a more rapid biochemical progression in a subgroup of patients, and that further analysis of this subgroup is warranted.
Просмотров: 69 ecancer
Neoadjuvant abiraterone acetate plus leuprolide acetate for localised high-risk prostate cancer
 
05:04
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Eleni Efstathiou, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a study that evaluated the clinical and biological heterogeneity of response and resistance to neoadjuvant abiraterone acetate, a prodrug of abiraterone, a CYP17 inhibitor that lowers serum testosterone, plus leuprolide acetate, a luteinizing hormone-releasing hormone agonist (LHRHa), versus LHRHa for patients with localised high-risk prostate cancer.
Просмотров: 622 European Medical Group
Long-Term Results of Post-Prostatectomy Radiotherapy
 
01:25
Douglas M. Dahl, MD, FACS, discusses the long-term results of post-prostatectomy radiotherapy.
Просмотров: 663 Targeted Oncology
ASCO 2018: Latest Developments in Non-Metastatic & Metastatic Castration-Resistant Prostate Cancer
 
18:54
Dr Neal Shore is joined by Dr Simon Chowdhury, Prof Matthew Smith and Prof Boris Hadaschik at the ASCO 2018 conference in Chicago. The discussion opens with comments on the day's poster sessions here at ASCO 2018, including genomic profiling of tumours from mCRPC patients, which gives promising findings. Following this there is a discussion about the P3 SPARTAN trial, investigating Association of metastasis-free survival (MFS) and overall survival (OS) in nonmetastatic castration-resistant prostate cancer (nmCRPC), led by Prof Smith. Prof Hadaschik comments on the Phase 2 randomised cross-over trial of abiraterone + prednisone (ABI+P) vs enzalutamide (ENZ) which give 2nd line therapy results. He believes the results point towards no large difference between the drugs, and at this point in time it should be down do a discussion with the clinician and patient. The panel discuss this further in the context of their own work. Dr Chowdhury comments on the Phase II randomised trial; Olaparib combined with abiraterone in patients with mCRPC, and describes why he believes some of the results were unexpected, and also discusses some of the toxicities. This leads on to Cora Sternberg's randomised phase 2 study investigating 3 dosing regimens of radium-223 dichloride (Ra-223) in bone metastatic castration-resistant prostate cancer (mCRPC) with comments from Prof Smith particularly highlighting the changes in toxicity as the dose increased. The discussion ends with a roundup of the Australian study with Lutetium and PSMA Gallium, Prof Hadaschik gives a detailed overview and opinion. This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).
Просмотров: 180 ecancer
Breast Cancer And Hormone Therapy
 
02:19
The Women’s Health Initiative was a major federally funded study.  In 2002 researchers suspended one phase of the study after noticing women who took estrogen and progestin had increased health risks.  Now a new study that followed those women for three years after the trial was halted indicates they were still at a higher risk for some health conditions even after they stopped taking hormones. 
Просмотров: 216 mymedicalreports
Treating High-Risk Localized Prostate Cancer
 
09:46
Multiple treatment options exist for patients with high-risk localized or advanced prostate cancer, making the optimal treatment decision difficult, since it will likely require multiple modalities. In this segment, panelists explore the intricacies of treating patients in this setting. For more from this discussion, visit http://www.onclive.com/peer-exchange/prostate-guidelines
Просмотров: 2854 OncLiveTV
Hi-Risk/Recurrent/Advanced PCa Men and Caregivers - March 28, 2017
 
02:06:29
Neuropathy from hormone therapy; PSA patterns post neo-adjuvant radiation; timing intervention when first CRPC; medical oversights before procedures; ED & hormone therapy; Zometa and bone pain
Просмотров: 26 Answer Cancer Foundation